[Mycologic monitoring of newborn infants at risk during preventive administration of nystatin].
Altogether 80 newborns at risk were prophylactically treated with 3 x 150,000 IU nystatin/d per os for 14-21 d respectively on every second day for 14-21 d. The content of yeasts in the faeces was determined. In preterm infants with birth-weight below 1500 g the intestinal yeasts--especially Candida albicans--persisted much longer during nystatin application than in infants with higher birthweight and longer gestation-time. In newborns at risk, daily nystatin doses of 3 x 150,000 IU/d are recommended for the duration of disposition for systemic candidosis.
Blaschke-Hellmessen
R
R
Institut für Medizinische Mikrobiologie, Medizinischen Akademie Carl Gustav Carus, Dresden.
Schwarze
R
R
D002176:Candida albicans / Q000187:drug effects / Q000302:isolation & purification; D002177:Candidiasis / Q000097:blood / Q000382:microbiology / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005243:Feces / Q000737:chemistry / Q000382:microbiology; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000097:blood / Q000382:microbiology / Q000517:prevention & control*; D008657:Metabolic Clearance Rate; D009761:Nystatin / Q000008:administration & dosage* / Q000493:pharmacokinetics
D009761:Nystatin
Mykologische Uberwachung von Risikoneugeborenen während der prophylaktischen Verabreichung von Nystatin.